Literature DB >> 23712805

Recent advances towards the clinical application of DNA vaccines.

A D Bins1, J H van den Berg, K Oosterhuis, J B A G Haanen.   

Abstract

DNA vaccination is an attractive method for therapeutic vaccination against intracellular pathogens and cancer. This review provides an introduction into the DNA vaccination field and discusses the pre-clinical successes and most interesting clinical achievements thus far. Furthermore, general attributes, mechanism of action and safety of DNA vaccination will be discussed. Since clinical results with DNA vaccination so far show room for improvement, possibilities to improve the delivery and immunogenicity of DNA vaccines are reviewed. In the coming years, these new developments should show whether DNA vaccination is able to induce clinically relevant responses in patients.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23712805

Source DB:  PubMed          Journal:  Neth J Med        ISSN： 0300-2977            Impact factor:   1.422


  10 in total

Review 1.  Advances in the study of HLA-restricted epitope vaccines.

Authors:  Lingxiao Zhao; Min Zhang; Hua Cong
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

2.  Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques.

Authors:  Dibyadyuti Datta; Geetha P Bansal; Brooke Grasperge; Dale S Martin; Mario Philipp; Dietlind Gerloff; Barry Ellefsen; Drew Hannaman; Nirbhay Kumar
Journal:  Vaccine       Date:  2017-11-10       Impact factor: 3.641

3.  Combinations of various CpG motifs cloned into plasmid backbone modulate and enhance protective immunity of viral replicon DNA anthrax vaccines.

Authors:  Yun-Zhou Yu; Yao Ma; Wen-Hui Xu; Shuang Wang; Zhi-Wei Sun
Journal:  Med Microbiol Immunol       Date:  2014-09-30       Impact factor: 3.402

4.  Targeting DNA vaccines to myeloid cells using a small peptide.

Authors:  Chunting Ye; Jang Gi Choi; Sojan Abraham; Premlata Shankar; N Manjunath
Journal:  Eur J Immunol       Date:  2014-11-02       Impact factor: 5.532

Review 5.  The rabbit papillomavirus model: a valuable tool to study viral-host interactions.

Authors:  Nancy M Cladel; Xuwen Peng; Neil Christensen; Jiafen Hu
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

6.  Vaccination with a piggyBac plasmid with transgene integration potential leads to sustained antigen expression and CD8(+) T cell responses.

Authors:  Pietro Bertino; Johann Urschitz; Fukun W Hoffmann; Bo Ra You; Aaron H Rose; Woo Hyun Park; Stefan Moisyadi; Peter R Hoffmann
Journal:  Vaccine       Date:  2014-02-07       Impact factor: 3.641

7.  A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant.

Authors:  Naoya Miura; Sharif M Shaheen; Hidetaka Akita; Takashi Nakamura; Hideyoshi Harashima
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

8.  Draft Genome Sequence of the Plasmid-Free Lactococcus lactis subsp. lactis Strain LMG 19460.

Authors:  Inês N Silva; Sofia Duarte; Leonilde M Moreira; Gabriel A Monteiro
Journal:  Genome Announc       Date:  2017-04-20

Review 9.  Recent Developments in Preclinical DNA Vaccination.

Authors:  Kenji Okuda; Yoshiyuki Wada; Masaru Shimada
Journal:  Vaccines (Basel)       Date:  2014-01-13

Review 10.  Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials.

Authors:  Irina Petrushina; Armine Hovakimyan; Indira S Harahap-Carrillo; Hayk Davtyan; Tatevik Antonyan; Gor Chailyan; Konstantin Kazarian; Maxim Antonenko; Amandine Jullienne; Mary M Hamer; Andre Obenaus; Olga King; Karen Zagorski; Mathew Blurton-Jones; David H Cribbs; Harry Lander; Anahit Ghochikyan; Michael G Agadjanyan
Journal:  Neurobiol Dis       Date:  2020-02-28       Impact factor: 5.996
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.